Disaggregation of bone into crystals

Summary The sizes, shapes, and organizational states of the crystals in bone are studied by systematic disaggregation of the mineral phase. This is achieved by oxidizing the organic phase with sodium hypochlorite, dispersing the resultant particles by sonication, and separating the crystal aggregates from the crystal monomers by gravity setting in ethanol. Six different bones are compared. Bones in which crystals are intimately associated with the collagen fibrils mostly disaggregate into crystal monomers. In dense bones, where the crystals are mostly located between fibrils, they tend to persist as “fused” aggregates. All the crystals are tabular or plate-shaped. In bones in which the majority of crystals are associated with the collagen fibrils, just less than 90% of the crystals are shorter than about 450 ? in length. Their widths are on the average about 250 ?, almost an order of magnitude larger than the diameters of individual gap regions within the collagen fibril. The notion that one crystal is located in one gap region is therefore untenable and a reevaluation of the relations between collagen and mineral in bone is necessary.     

前路槽式减压长方体髂骨植骨固定治疗颈椎骨折

颈椎骨折常合并有不同程度的脊髓神经功能损伤及颈椎不稳定,对颈脊髓损伤治疗的目的是恢复颈椎的生理解剖关系,重建脊柱的稳定性,防止神经组织的继发性损伤,促进神经功能的恢复,早期无痛情况下的功能康复。2000年8月至2004年8月应用前路槽式减压自体长方体髂骨植骨钛合金钢板固定治疗下颈椎骨折46例,效果满意,总结如下。1临床资料本组46例,均为男性,年龄21~62岁,平均47·3岁。受伤原因:交通事故伤26例,坠落伤20例。骨折部位:C33例,C412例,C516例,C610例,C4、C5同时骨折5例。骨折类型:垂直压缩性骨折4例,屈曲型压缩性骨折23例,过伸型压缩…     

Treatment of osteoporosis in men

Osteoporosis in men is recognised worldwide as an important and increasing public health problem. The causes are more heterogeneous than those in women. About 50% are diagnosed as secondary cases. In some secondary forms of osteoporosis the specific diagnosis results in additional therapeutic options (e.g. androgen therapy in proven hypogonadism). The basic therapy for osteoporosis in men is no different to that in postmenopausal women, namely recommendations for counteracting modifiable risk factors, especially with regard to diet, physical exercise, and calcium and vitamin D supplementation. Concerning specific drug medications, however, even today there is still a therapeutic dilemma in male osteoporosis. While older substances (e.g. calcitonin, fluoride, alfacalcidol) are approved for both sexes, all newer medications have primarily been approved for the treatment of postmenopausal osteoporosis. Health authorities request studies in purely male populations. For new drugs, fracture data are necessary while for new substances within a class (e.g. bisphosphonates), at the very least consistent effects on bone mineral density (BMD) and bone turnover markers are requested. Due to these regulatory rules, ibandronate, teriparatide and strontium ranelate are not approved in the European Union. Some years ago, alendronate was the first bisphosphonate that was approved for the treatment of men with osteoporosis, based on consistent results from two independent male studies using a daily 10 mg dosage. Very recently risedronate was approved by the FDA and EMEA. A randomised, placebo-controlled multicentre trial of 285 male patients showed, after 2 years, a 5.8% increase in lumbar spine BMD in the risedronate 35 mg once weekly group vs 1.2% in the placebo group. In a prospective controlled study on 316 men with primary or secondary osteoporosis we found, after 12 months, a lumbar spine BMD of +4.7% vs +1.0% in controls. The number of patients with one or more new vertebral fractures was 8 in the risedronate group and 20 in the placebo group (a fracture reduction of 60%). Furthermore, we found a significantly smaller decrease in height and a steeper decrease in back pain in the risedronate group. Risedronate is the first oral bisphosphonate available for men with the more comfortable once weekly dosage.     

经皮椎体成形术中骨水泥对老年骨质疏松症患者凝血功能的影响

目的 观察经皮椎体成形术(PVP)中骨水泥对老年骨质疏松症患者凝血功能的影响.方法 于椎弓根穿刺前10 min、注入骨水泥后1、20 min、2 h分别抽血检测11例患者的凝血功能相关指标,包括血浆凝血酶原时间(PT)、活化的部分凝血酶原时间(APTT)、血浆纤维蛋白原(FIB)和鱼精蛋白副凝固实验(3P实验),并汇总数据进行统计学分析.结果 PVP中骨水泥注入后20 min,PT缩短、FIB增高、3P实验阳性率升高(P<0.05),骨水泥注入2 h后基本恢复至注入前水平.除1例患者PTA术后2 h稍高于正常值(126%),其余患者各个时间点的各项指标均在正常参考值范围内.结论 PVP术中注入骨水泥对于凝血功能正常的患者基本安全,但在注入后会产生一过性轻微的高凝倾向.     

空心钉和骨圆针固定治疗股骨转子间骨折的力学随机对照试验

目的:通过与4枚斯氏针固定比较,利用生物力学方法评价多枚空心钉固定股骨转子骨折的适应证和可靠性。方法:使用Sawbone股骨模型,模拟EvansⅢA型骨折,分别用2种多枚空心钉方法(矩外空心钉和矩内空心钉法)及多枚骨圆针固定,在CSS-11101力学实验机上进行载荷试验,取300 N载荷下股骨头垂直位移和张口位移数值,比较3种方法的轴向刚度。通过扭转实验比较3种固定方法的抗扭转能力。结果:3种固定方法在轴向刚度方面差异有统计学意义(P<0.05),而抗扭转能力方面差异无统计学意义(P>0.05)。结论:矩外空心钉固定力学性能相似于4枚骨圆针,而矩内空心钉固定弱于4枚骨圆针。应用多枚空心钉固定应选择稳定型股骨转子间骨折。     

切开复位内固定治疗Gartland Ⅲ型肱骨髁上骨折

目的探讨切开复位内固定治疗Gartland Ⅲ型肱骨髁上骨折的疗效。方法1999年10月-2005年4月，对62例平均年龄7．5岁的患儿，应用切开复位克氏针固定治疗Gartland Ⅲ型肱骨髁上骨折。其中伸直尺偏型41例，伸直桡偏型18例，伸直中间型3例；无伴发血管、神经损伤和筋膜室间隔综合征。闭合性骨折47例，开放性骨折15例。结果术后56例获得随访，随访时间为6～15个月，平均11．5个月。所有骨折均获得愈合。根据Flynn标准进行疗效评价，其中优22例（占39．3％），良21例（37．5％），可9例（16．1％），差4例（7．1％）。伤后8h内手术的优良率为89．7％，伤后8h后手术的优良率为63．0％。直接手术治疗的优良率为90．1％，曾接受手法复位的优良率为67．7％。结论切开复位内固定治疗Gartland Ⅲ型肱骨髁上骨折可取得满意的疗效，是安全、有效的治疗方法。     

前后路联合三维矫形手术治疗青少年特发性僵硬型胸椎侧凸

目的:评价前路松解联合后路三维矫形治疗青少年特发性僵硬型胸椎侧凸的效果,探讨术中、术后并发症的预防措施。方法:青少年特发性僵硬型胸椎侧凸34例,男5例,女29例;年龄8～21岁,平均14.7岁。均为右侧凸。均采用经前路松解植骨融合联合后路三维矫形内固定治疗,其中前路经胸入路26例,胸腔镜前路松解植骨融合矫形术8例。随访时均摄全脊柱X线片。术前、术后所摄X线片进行以下各项测量指标比较:Cobb角、顶椎的旋转度、下融合椎旋转度、躯干偏移距离。随访时观察有无脊柱失平衡、假关节形成及其他并发症的发生。结果:全部病例均获随访,时间12～39个月,平均22个月。所有患者Cobb角术后平均矫正率80.62%,其中18例患者出现矫正度数丢失,丢失度数3°～10°,平均4.3°(术后平均14.2°,1年后随访平均18.5°)。所有患者术后胸椎生理性后凸得到重建。术后胸椎融合弯顶椎的旋转改善率62.91%,下融合椎旋转改善率47.60%,躯干偏移平均距离3.3mm,未见脊柱失平衡现象。围手术期并发症包括低氧血症1例,胸腔积液2例,均经保守治疗后痊愈。术后6个月肺功能检查,未见有明显下降。脊柱胸弯融合段未发现假关节形成。结论:前路松解联合后路矫形内固定植骨融合治疗青少年特发性僵硬型胸椎侧凸可明显改善顶椎的旋转度,得到满意的三维矫形效果。术前积极准备、合理手术设计,术中严格操作,术后重视预防并发症能减少手术并发症的发生。     

手法治疗肘关节错缝86例

2000年1月-2005年10月共治疗肘关节错缝86例,临床效果满意,现报告如下。1临床资料86例中男61例,女25例;年龄13~46岁。受伤机制:均为跌倒时手掌着地,肘关节过伸导致。摄X线片未见骨折及关节异常。肘关节伸屈活动障碍,伸20°~40°,屈90°~110°,屈伸平均(70·57°±3·01°)的活动范围。肘关节轻度肿胀,以内后方为甚,压痛点为尺骨半月切迹的内侧,强作旋后活动时会引起剧烈疼痛,肘三角正常。受伤至就诊时间1~3 d,平均1·5 d。2治疗方法2·1复位左肘错缝者坐于靠背椅上,助手立于患者侧背后方,紧握患者上臂,术者于患者前侧,左手握患者腕部,右手…     

过氧化物酶体增殖物激活受体γC161T基因多态性与糖皮质激素性骨质疏松症的关系

目的 探讨中国人过氧化物酶体增殖物激活受体γ(PPARγ)基因外显子6 C161T多态性与糖皮质激素性骨质疏松症(GIO)的相关关系。方法 应用聚合酶链反应-限制性片段长度多态性(PCR-RELP)方法测定208例正常健康人（Ⅰ组）、168例非GIO患者（Ⅱ组）和104例GIO患者（Ⅲ组）PPARγ基因外显子6 C161T的基因型。应用双能X线骨密度仪(DEXA)测定股骨、腰椎等部位的骨密度。 结果 外显子6 C161T有CC、CT、TT 3种基因型。GIO组CC基因型频率显著低于正常对照组；CT和TT基因型频率显著高于正常对照组。非GIO组、应用激素组（GIO组＋非GIO组）与正常对照组比较，各基因型频率差异均无统计学意义。正常对照组C161T的CC基因型组各部位的骨密度有高于CT和TT基因型组的趋势，但差异无统计学意义。非GIO组和GIO组C161T的CC基因型组腰椎的骨密度明显高于CT和TT基因型组 (P ＜ 0.05)，分别为非GIO组CC型（1.04±0.17） g/cm2，CT+TT型（1.02±0.07） g/cm2；GIO组CC型（0.94±0.12） g/cm2，CT+TT型（0.83±0.08） g/cm2。经年龄、体重指数等因素校正后，差异仍有统计学意义(P ＜ 0.05）。 结论 PPARγ基因C161T基因型在正常人和应用激素患者之间无明显差异，它可能与肾小球肾炎的发病无关。C161T基因型在GIO组和正常对照组之间差异有统计学意义，它可能与糖皮质激素性骨质疏松症的发病有关。PPARγ基因C161T多态性与应用糖皮质激素患者腰椎的骨密度有关。等位基因C可能是骨量的保护因子，它可能与应用糖皮质激素后骨量的丢失有关。